GLP-1s have real value, but not all people respond to them the same way. The real question isn’t just what these drugs cost, but who they’re working for — and our healthcare system doesn’t have a reliable way to reconcile the two.
The post America Is Betting Big On GLP-1s. It Doesn’t Have To Be A Gamble appeared first on MedCity News.
